The latest update is out from vTv Therapeutics ( (VTVT) ).
On February 24, 2025, vTv Therapeutics announced that Steven Tuch, its Executive Vice President and Chief Financial Officer, plans to resign effective March 21, 2025. The company is actively seeking a successor through an external search, and Mr. Tuch’s departure is not due to any disagreements with the company or its auditors.
More about vTv Therapeutics
vTv Therapeutics Inc. operates in the pharmaceutical industry, focusing on the development of orally administered small molecule drug candidates to fill unmet medical needs.
YTD Price Performance: 37.36%
Average Trading Volume: 15,466
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $59.45M
For an in-depth examination of VTVT stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com